Transthyretin Amyloidosis (ATTR)
European Society of Cardiology (ESC) 2025
Congress Details
August 29 - September 1, 2025
Madrid, Spain
The material below is provided to support scientific exchange and pertains to select congress resources. Any content about investigational therapeutics or investigational uses of locally approved products does not establish the safety or efficacy of these therapeutics or uses, and there is no guarantee of local regulatory approval.
All congress materials are copyrighted by Alnylam. Permission is required to copy or distribute.
For questions beyond a product’s authorized indications or for information not available here, please contact Alnylam Medical Information.
Congress Materials
Presentation Type
Location
Presenter
Related Materials
Transthyretin Amyloidosis (ATTR)
European ATTR Amyloidosis Meeting (EU-ATTR) 2025
Transthyretin Amyloidosis (ATTR)
Canadian Association for Population Therapeutics (CAPT) 2025
Transthyretin Amyloidosis (ATTR)
Vutrisiran in Transthyretin Amyloidosis: A Pooled Safety Analysis of HELIOS-A and HELIOS-B
JACC: Advances
Transthyretin Amyloidosis (ATTR)
Effects of Vutrisiran on Cardiac Structure and Function in Patients with Transthyretin Amyloidosis with Cardiomyopathy: Secondary Outcomes of the HELIOS-B Trial
Nature Medicine
Transthyretin Amyloidosis (ATTR)
Impact of Vutrisiran on Cardiac Biomarkers in Patients With Transthyretin Amyloidosis With Cardiomyopathy From HELIOS-B
Journal of the American College of Cardiology
Transthyretin Amyloidosis (ATTR)
Effects of Vutrisiran on Cardiac Function and Outcomes in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Journal of the American College of Cardiology
